Nbryo Chairman shares the value of Non-Dilutive Funding

“For early-stage and high-growth companies like ours, time is the most limited resource.” – Gerard Davis, Nbryo Chairman.

Start here – tell us more about you.

With limited time and resources, securing non-dilutive funding can be complex. Get in touch with an expert at Scale Impact to streamline your funding strategy and secure financial support efficiently.

 
Scale Impact’s CEO, Camilla Roberts, recently sat down with Gerard Davis, former CEO and current Chairman of Nbryo, to discuss how strategic non-dilutive funding has accelerated the company’s commercialisation. With Scale Impact’s support, Nbryo has secured AU$1.3 million through the Industry Growth Program grant, advancing its technology to enhance precision breeding, optimise herd composition, and drive more efficient, sustainable livestock production.
 
Camilla: 

Gerard, it’d be great to hear from you about what does Nbryo do.

Gerard:

Nbryo is a company in the livestock genetics business where we’re developing a platform that will accelerate genetic change dramatically and enable both beef and dairy producers to have increased productivity and to adapt to climate change and to lower their methane production.

We’ve engaged with the Bill and Melinda Gates Foundation, because it could see the potential for the Nbryo platform to make the dramatic and scale change in livestock productivity and methane emissions in the markets where they’re most interested, which are low to medium income countries.

Camilla:

What prompted you to want to work with Scale Impact?

Gerard:

I think there’s a couple of things that prompted us. First of all, the time challenge for management to develop project proposals for grant funding is significant, and we were at a point where it was, very challenging for us to do that. Secondly, I have great respect for your capabilities and have seen a number of arenas where you’ve been able to deliver significant outcomes.

We were clearly wanting to pursue as much non-dilutive funding as we could, but didn’t have the resources, from a time standpoint, and we had great confidence in the person we were dealing with to deliver.

Camilla: 

Have you got any thoughts or reflections on why that was valuable to the company?

Gerard: 

Yeah, look, one of the key technologies that we’re developing, which it really is a groundbreaking piece of technology, is a device that enables the average producer to transfer an embryo so they can get access to the genetics in a way that they currently can’t.

And that device, we’ve been doing research on now for nearly three years. But it needs to go through the commercialisation process, and the opportunity of the Industry Growth Program is to support what we were trying to do, which is take it

We have to run pilot trials to develop the prototypes, but also ultimately to prove that the thing is going to deliver the value that producers need.

Scale Impact was able to help us develop both of those proposals, keep them integrated together, so they were serving different purposes but had to contribute to the whole, which was to move us from a set of prototype subsystems to an ultimately a commercial product in the market by next year. And so, very pleased that those two programs we’ve been successful in and we’re really looking forward to getting on with that work and delivering the device outcome.

Camilla: 

So, we’ve been successful together in securing the Industry Growth Program grant that was 1.3 million for Nbryo to move its device prototype work forward.

Tell me more about why that’s important to the business.

Gerard: 

Yeah, so we’ve developed this device, through to a set of subsystem prototypes, and what it does is it enables the average commercial producer to be able to transfer an embryo, with a bit of training. We needed to move that through to commercialisation and we understood that the Industry Growth Program was set up for that, and so we engaged Scale Impact to help us attract 1.3 million dollars in grant funding, to support us through to that position, and we were successful, and we’re now underway with that work; first design for manufacturing, and then ultimately getting through to manufacture that embryo transfer device, which is a critical technology for the Nbryo platform.

Camilla: 

Gerard, were there any unexpected insights or benefits from working together that you hadn’t anticipated at the outset?

Gerard: 

We had a couple of dedicated projects that we were focused around. But, in addition to that, we talked about developing strategy for non-dilutive funding and that was extremely valuable for us. And, when presented to our board committee, they were very supportive of that approach and could see the benefits.

So, I think beyond the specific projects, a major advantage working with you, Camilla, has been the ability to look at a more holistic approach to non-dilutive funding. It’s been quite valuable for us, and it’s indicated a way forward for us, that is going to be valuable for the company as we scale up to the next phase.

Camilla: 

What would you say to other businesses considering working with Scale Impact?

Gerard: 

So I’ve already recommended Scale Impact to a number of other businesses that I’m in contact with. And the reason is quite simple. Most of the early-stage companies similar to us are in the same situation.

They’re resource poor and the model that Scale Impact uses enables you to commit resource to non-dilutive funding, in a way that means that it’s not a huge impost on the business. And because of that, there is an alignment, and it means that the process pieces are dealt with by somebody who knows what they’re doing, has done it many times before and so it’s a lot more efficient than if you were having to discover the process off your own bat, and essentially reinvent the wheel every time.

Camilla:

I think that’s a really interesting point. I find a lot of CEOs still want to try and do it themselves. So, what advice would you give to a CEO?

Gerard: 

I think it’s the case that senior people in early-stage and high growth companies like ours, their time is limited.

It’s probably the most limited resource is the amount of time they have. And so, taking on the process of learning how to submit under a particular program and all the nuances involved; and some of these programs are not straightforward. Having to learn all that yourself rather than going with somebody who’s already done it on multiple occasions and can cut through and get you to where you need to get to quite quickly is value for the business; is the way that we’ve certainly looked at it.

I think I would add that we had a couple of goes where we failed, and we still committed all that executive time. But we failed and the reason that we failed, on two occasions, was more related to process than to content.

And that’s the risk that you take if you’re not familiar with these programs, that you will make a mistake that you’re not even aware of, and don’t have the opportunity to correct.

Camilla: 

What sort of business do you think is ideal to work with Scale Impact?

Gerard: 

Companies that are embryonic probably have limited benefit and companies that are highly advanced probably have their own people who do this work.

So, it’s really from relatively early stage startup businesses through to growth, particularly growth, where non-dilutive programs can have their most impact.

As your name says, when you’re scaling, that’s where the impact can be greatest from non-dilutive funding. Because you want to be putting all your capital towards what it is you’re trying to achieve.

Camilla: 

Is there anything else you’d like to share?

Gerard: 

It’s a pleasure working with Camilla. What we were trying to do was reasonably complex and had to be done quite quickly, and Camilla’s very easy to work with, she’s very clear on what she needs, and I think that helped the process work.

Camilla: 

Thank you very much. Best of luck.

If you’re scaling your business and need the right funding strategy without sacrificing executive time, let Scale Impact help you secure non-dilutive funding to accelerate your commercialisation journey.
 
Start here – tell us more about you.